Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
3
38%
Ph phase_1
2
25%
Ph phase_2
3
38%

Phase Distribution

2

Early Stage

3

Mid Stage

3

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
2(25.0%)
Phase 2Efficacy & side effects
3(37.5%)
Phase 3Large-scale testing
3(37.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Active(2)
Completed(4)
Other(2)

Detailed Status

Completed4
unknown2
Not yet recruiting2

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (25.0%)
Phase 23 (37.5%)
Phase 33 (37.5%)

Trials by Status

unknown225%
completed450%
not_yet_recruiting225%

Recent Activity

0 active trials
Showing 5 of 8
completedphase_1

Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer

NCT03403049
not_yet_recruitingphase_1

Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer.

NCT06888674
not_yet_recruitingphase_3

HR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cancer

NCT06217042
unknownphase_2

MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer With High Risk and Locally Advanced Disease

NCT04089150
completedphase_3

Gemcitabine With or Without Capecitabine in Treating Patients With Advanced Pancreatic Cancer

NCT00030732
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT03403049Phase 1

Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer

Completed
NCT06888674Phase 1

Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer.

Not Yet Recruiting
NCT06217042Phase 3

HR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cancer

Not Yet Recruiting
NCT04089150Phase 2

MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer With High Risk and Locally Advanced Disease

Unknown
NCT00030732Phase 3

Gemcitabine With or Without Capecitabine in Treating Patients With Advanced Pancreatic Cancer

Completed
NCT01077427Phase 3

Hyperthermia European Adjuvant Trial

Unknown
NCT01472770Phase 2

A Phase II Study of Gemcitabine and Capecitabine for Treatment Resistant, Metastatic Colorectal Cancer

Completed
NCT00159445Phase 2

Capecitabine and Gemcitabine in Patients With Metastatic Colorectal Cancer

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8